Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer.

ABSTRACT:

Purpose

Circulating tumor DNA (ctDNA) sequencing provides a minimally invasive method for tumor molecular stratification. Commercial ctDNA sequencing is increasingly used in the clinic, but its accuracy in metastatic prostate cancer is untested. We compared the commercial Guardant360 ctDNA test against an academic sequencing approach for profiling metastatic prostate cancer.

Patients and methods

Plasma cell-free DNA was collected between September 2016 and April 2018 from 24 patients with clinically progressive metastatic prostate cancer representing a range of clinical scenarios. Each sample was analyzed using Guardant360 and a research panel encompassing 73 prostate cancer genes. Concordance of somatic mutation and copy number calls was evaluated between the two approaches

SUBMITTER: Taavitsainen S 

PROVIDER: S-EPMC7446428 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature